Skip to main content
 

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle 
05/10/17WAVE Life Sciences Reports First Quarter 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced financial results for the first quarter ended March 31, 2017. “The beginning of 2017 was marked by continued advancement of our lead programs in HD and DMD and substantial progress in our collaboration with Pfizer. Our two HD pro... 
Printer Friendly Version
04/12/17WAVE Life Sciences Prices Public Offering of 4,166,667 Ordinary Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 12, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, announced today the pricing of its previously announced underwritten public offering of 4,166,667 of its ordinary shares at a price to the public of $24.00 per ordinary share. Net proceeds to WAVE Life Sciences from the offering are expected to be approximate... 
Printer Friendly Version
04/11/17WAVE Life Sciences Announces Proposed Public Offering of Ordinary Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 11, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, announced today that it has commenced an underwritten public offering of its ordinary shares. In connection with the offering, WAVE intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in ... 
Printer Friendly Version
03/16/17WAVE Life Sciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Business Update
On track to take first three lead programs into the clinic in 2017 Clinical trials expected to commence in Huntington’s disease mid-2017, Duchenne Muscular Dystrophy second half of 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 16, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today reported financial results for the fourth quarter and ... 
Printer Friendly Version
02/06/17WAVE Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2017-- WAVE Life Sciences Ltd. (NASDAQ:WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences: Leerink Partners Global Healthcare Conference 2017 Wednesday, February 15th at 1:30... 
Printer Friendly Version
01/06/17WAVE Life Sciences 2017 Pipeline Update
Three Lead Neurology Programs to Enter Clinic in 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced updates to its clinical pipeline for 2017. “2017 will be an important year for WAVE as we transition our two lead candidates in Huntington’s disease and our exon-skipping candida... 
Printer Friendly Version